Precision Air’s Zero-particle Airflow System, SurgicAir® Zero, Debuts in Twin Cities Operating Rooms

Precision Air announced today the completion of its fourth SurgicAir® Zero O.R. Airflow System at TRIA Orthopedic Center Woodbury, a specialty orthopedic and urgent care facility in the Twin Cities metro area.

Precision Air advises this groundbreaking technology produces zero-particle air in operating rooms (O.R.s) and in health care settings, something that has never before been achieved. TRIA is currently testing it at their Woodbury location.

The SurgicAir® Zero System is a quantum leap in O.R. airflow quality – far exceeding today’s minimum standards. While numerous studies have proven airborne pathogens are a major source of contamination in the O.R., minimum codes for air quality have not kept up.

“TRIA’s investment in the SurgicAir® Zero System shows an innovative approach to infection control. The need for this Covid-capable technology is growing as health care leaders strive to protect patients and create a safe, comfortable experience for everyone in the room,” said Derek Weinschenk, Precision Air president.

This technology also enables TRIA to continue critical surgeries during the COVID-19 pandemic with fewer risks to surgical staff and patients. Testing data shows airborne contaminants from procedures like intubation or cauterization are more quickly controlled, leading to 75% less exposure for everyone in the room compared to basic ventilation systems.

Surgeons and health care leaders at TRIA who have implemented the system have shared their enthusiasm for the technology.

“Our SurgicAir® Zero System provides a comfortable, quiet O.R. environment. However, it is the peace of mind of having clean air in our surgical field that I find to be the largest benefit of this system,” said Dr. Gavin Pittman, orthopedic surgeon at TRIA Orthopedics.

“When we were planning for our TRIA Woodbury Surgery Center, we knew we wanted the latest technology for infection prevention. SurgicAir affords us additional protection for our patients with the cleanest air space above the operating table,” said Mary Haugen, director of TRIA’s ambulatory surgery centers.

In addition to the surgical suites at TRIA Woodbury, the SurgicAir® Zero Airflow System is currently operational at Presbyterian Hospital in New Mexico.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”